A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Binimetinib (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions
- Sponsors Array BioPharma; Novartis
- 07 Jun 2017 Biomarkers information updated
- 26 May 2017 Planned End Date changed from 30 Jun 2017 to 31 Dec 2017.
- 18 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History